Condition
Dedifferentiated Chondrosarcoma
Total Trials
4
Recruiting
0
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
4Total
P 2 (4)
Trial Status
Active Not Recruiting3
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04458922Phase 2Active Not Recruiting
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
NCT01267955Phase 2Active Not Recruiting
Vismodegib in Treating Patients With Advanced Chondrosarcomas
NCT03449108Phase 2Active Not Recruiting
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
NCT02821507Phase 2Completed
Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
Showing all 4 trials